keyword
MENU ▼
Read by QxMD icon Read
search

Garcia manero

keyword
https://www.readbyqxmd.com/read/29779988/leadless-pacemaker-implantation-in-a-transplanted-heart
#1
José Luis Martínez-Sande, Javier García-Seara, Laila González-Melchor, Moisés Rodríguez-Mañero, Inés Gómez-Otero, José Ramón González-Juanatey
No abstract text is available yet for this article.
May 17, 2018: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29763917/relevance-of-dementia-in-atrial-fibrillation-patients-within-a-specific-european-health-care-area
#2
Moisés Rodríguez-Mañero, Estrella López-Pardo, Alberto Cordero, Omar Kreidieh, José Novo Platas, Luis Valdés, Adrian Cid-Menendez, Javier García-Seara, María Pereira-Vázquez, Jose-Luis Martínez-Sande, Alberto Ruano, Carlos Peña-Gil, Pilar Mazón, Jose María García-Acuña, José Ramón González-Juanatey
INTRODUCTION: Atrial fibrillation might increase the risk of dementia. We aim to test the hypothesis that dementia could reclassify the actual risk of stroke and death predicted by the CHA2DS2-VASc in patients with atrial fibrillation (AF). METHODS: A prospective study performed in a specific health care area. RESULTS: From our health care area (n = 348,985), throughout 2013, AF was codified in 7,990 (2.08%). Mean age was 76.83 ± 10.5, mean CHA2DS2-VASc = 3...
May 15, 2018: Neuroepidemiology
https://www.readbyqxmd.com/read/29749401/blast-phase-chronic-myelomonocytic-leukemia-mayo-mdacc-collaborative-study-of-171-cases
#3
Mrinal M Patnaik, Ana A Pierola, Rangit Vallapureddy, Fevzi F Yalniz, Tapan M Kadia, Elias J Jabbour, Terra Lasho, Curtis A Hanson, Rhett P Ketterling, Hagop M Kantarjian, Ayalew Tefferi, Guillermo Garcia-Manero
No abstract text is available yet for this article.
April 25, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29741984/myc-protein-expression-is-an-important-prognostic-factor-in-acute-myeloid-leukemia
#4
Maro Ohanian, Uri Rozovski, Rashmi Kanagal-Shamanna, Lynne V Abruzzo, Sanam Loghavi, Tapan Kadia, Andrew Futreal, Kapil Bhalla, Zhuang Zuo, Yang O Huh, Sean M Post, Peter Ruvolo, Guillermo Garcia-Manero, Michael Andreeff, Steven Kornblau, Gautam Borthakur, Peter Hu, L Jeffrey Medeiros, Koichi Takahashi, Marisa J Hornbaker, Jianhua Zhang, Graciela M Nogueras-González, Xuelin Huang, Srdan Verstovsek, Zeev Estrov, Sherry Pierce, Farhad Ravandi, Hagop M Kantarjian, Carlos E Bueso-Ramos, Jorge E Cortes
As new drugs targeting MYC show clinical activity in acute myeloid leukemia (AML), understanding MYC expression in AML is of critical importance. We assessed MYC protein expression by immunohistochemistry in bone marrow of patients with untreated AML (n = 265). Overall, 90% of patients demonstrated MYC overexpression and MYC immunopositivity ≤6% was associated with superior complete remission (CR) duration of 23 months versus 12 months for MYC immunopositivity >6% (p = .028). Among 241 patients at higher risk for relapse, including those ≥55 years of age and patients with intermediate- and high-risk AML, MYC immunopositivity ≤6% conferred significantly superior median overall survival (OS) (24 versus 13 months; p = ...
May 9, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29724899/the-dot1l-inhibitor-pinometostat-reduces-h3k79-methylation-and-has-modest-clinical-activity-in-adult-acute-leukemia
#5
Eytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, Raoul Tibes, Jesus G Berdeja, Michael R Savona, Mojca Jongen-Lavrenic, Jessica K Altman, Blythe Thomson, Stephen J Blakemore, Scott R Daigle, Nigel J Waters, A Benjamin Suttle, Alicia Clawson, Roy Pollock, Andrei Krivtsov, Scott A Armstrong, Jorge DiMartino, Eric Hedrick, Bob Löwenberg, Martin S Tallman
Pinometostat (EPZ-5676) is a first-in-class, small-molecule inhibitor of the histone methyltransferase DOT1L. In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involving MLL rearrangements ( MLL-r ) resulting from 11q23 translocations. Fifty-one patients were enrolled into 6 dose escalation cohorts (n=26) and 2 expansion cohorts (n=25) at pinometostat doses of 54 and 90 mg/m2 /day by continuous intravenous infusion in 28-day cycles...
May 3, 2018: Blood
https://www.readbyqxmd.com/read/29702471/characterization-of-hybrid-microparticles-montmorillonite-composite-with-raspberry-like-morphology-for-atorvastatin-controlled-release
#6
Perla García-Guzmán, Luis Medina-Torres, Fausto Calderas, María Josefa Bernad-Bernad, Jesús Gracia-Mora, Baltasar Mena, Octavio Manero
In this work, we prepared a novel composite based on hybrid gelatin carriers and montmorillonite clay (MMT) to analyze its viability as controlled drug delivery system. The objective of this research involves the characterization of composites formed by structured lipid-gelatin micro-particles (MP) and MMT clay. This analysis included the evaluation of the composite according to its rheological properties, morphology (SEM), particle size, XRD, FT-IR, and in vitro drug release. The effect of pH in the properties of the composite is evaluated...
April 9, 2018: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29702001/clearance-of-somatic-mutations-at-remission-and-the-risk-of-relapse-in-acute-myeloid-leukemia
#7
Kiyomi Morita, Hagop M Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P Patel, P Andrew Futreal, Koichi Takahashi
Purpose The aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated patients with AML who received intensive induction chemotherapy and attained morphologic complete remission (CR) at day 30 were studied. Pretreatment and CR bone marrow were analyzed using targeted capture DNA sequencing. We analyzed the association between mutation clearance (MC) on the basis of variant allele frequency (VAF) at CR (MC2...
April 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29682723/improving-the-detection-of-patients-with-inherited-predispositions-to-hematologic-malignancies-using-next-generation-sequencing-based-leukemia-prognostication-panels
#8
REVIEW
Courtney D DiNardo, Mark J Routbort, Sarah A Bannon, Christopher B Benton, Koichi Takahashi, Steve M Kornblau, Rajyalakshmi Luthra, Rashmi Kanagal-Shamanna, L Jeffrey Medeiros, Guillermo Garcia-Manero, Hagop Kantarjian, P Andrew Futreal, Funda Meric-Bernstam, Keyur P Patel
Recognizing and referring patients with possible inherited cancer predisposition syndromes for appropriate genetic evaluation and testing provides insights into optimal patient treatment approaches and also can provide education and testing opportunities for family members. Next-generation sequencing (NGS)-based, targeted genotyping for somatic mutations is increasingly used in the diagnosis, prognostication, and treatment selection for patients with hematologic malignancies. However, certain mutations that may be somatically acquired can also be present as germline mutations in some individuals and families...
April 6, 2018: Cancer
https://www.readbyqxmd.com/read/29649579/prognostic-value-of-nutrition-status-in-the-response-of-cardiac-resynchronization-therapy
#9
Belén Alvarez-Alvarez, Javier García-Seara, Moisés Rodríguez-Mañero, Diego Iglesias-Alvarez, Jose L Martínez-Sande, Rosa M Agra-Bermejo, Xesús A Fernández López, Laila González-Melchor, Francisco Gude Sampedro, Carla Díaz-Louzao, José R González-Juanatey
BACKGROUND: Cardiac resynchronization therapy (CRT) is indicated in symptomatic heart failure (HF) patients after achieving optimal medical therapy. However, there are still a large percentage of patients who do not respond to CRT. Malnutrition is a frequent comorbidity in patients with HF, and it is associated with a poorer prognosis. Here, we evaluate the nutritional status of patients assessed by Controlling Nutritional Status (CONUT) score and its association with structural remodeling and cardiovascular events...
April 9, 2018: Indian Pacing and Electrophysiology Journal
https://www.readbyqxmd.com/read/29645075/results-of-second-salvage-therapy-in-673-adults-with-acute-myelogenous-leukemia-treated-at-a-single-institution-since-2000
#10
Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez, Tapan M Kadia, Elias Jabbour, Carlos E Bueso-Ramos, Susan M O'Brien, Marina Konopleva, Nitin B Jain, Naval G Daver, Elizabeth J Shpall, Richard E Champlin, Aron Simkins, Guillermo Garcia-Manero, Michael J Keating, Xuelin Huang, Jorge E Cortes, Sherry A Pierce, Farhad Ravandi, Emil J Freireich
BACKGROUND: The prognosis is poor for patients who have relapsed-refractory acute myelogenous leukemia (AML). Most published reports analyzed results from therapies in first-salvage AML or in studies that were conducted before 2000. Several novel agents and strategies are being tested for potential approval as treatment for patients with relapsed-refractory AML in second salvage. Therefore, it is important to establish the historic results of anti-AML therapies in this setting in the modern era...
April 12, 2018: Cancer
https://www.readbyqxmd.com/read/29616388/cardiac-resynchronization-therapy-response-in-heart-failure-patients-with-different-subtypes-of-true-left-bundle-branch-block
#11
Javier García-Seara, Diego Iglesias Alvarez, Belen Alvarez Alvarez, Francisco Gude Sampedro, Jose L Martínez Sande, Moisés Rodríguez-Mañero, Bahij Kreidieh, Xesus Alberte Fernández-López, Laila González Melchor, José Ramón González Juanatey
PURPOSE: Left bundle branch block (LBBB) configuration has been described as a predictor of response to cardiac resynchronization therapy (CRT). We investigated whether different subtypes of true LBBB configuration could help select patients with better response and clinical outcome. METHODS: This retrospective study included 198 consecutive LBBB patients implanted with a CRT. True LBBB was defined using the Strauss and the Predict study criteria. Echocardiographic response was evaluated by the reduction in left ventricular end-systolic volume (LVESV) and the increase in left ventricular ejection fraction (LVEF)...
April 3, 2018: Journal of Interventional Cardiac Electrophysiology: An International Journal of Arrhythmias and Pacing
https://www.readbyqxmd.com/read/29602570/successful-optimization-of-adalimumab-therapy-in-refractory-uveitis-due-to-beh%C3%A3-et-s-disease
#12
José Luis Martín-Varillas, Vanesa Calvo-Río, Emma Beltrán, Juan Sánchez-Bursón, Marina Mesquida, Alfredo Adán, María Victoria Hernandez, Marisa Hernández Garfella, Elia Valls Pascual, Lucía Martínez-Costa, Agustí Sellas-Fernández, Miguel Cordero-Coma, Manuel Díaz-Llopis, Roberto Gallego, David Salom, Norberto Ortego, José L García-Serrano, José-Luis Callejas-Rubio, José M Herreras, Ángel García-Aparicio, Olga Maíz, Ana Blanco, Ignacio Torre, David Díaz-Valle, Esperanza Pato, Elena Aurrecoechea, Miguel A Caracuel, Fernando Gamero, Enrique Minguez, Carmen Carrasco-Cubero, Alejandro Olive, Julio Vázquez, Oscar Ruiz-Moreno, Javier Manero, Santiago Muñoz-Fernández, Myriam Gandía Martinez, Esteban Rubio-Romero, F Javier Toyos-Sáenz de Miera, Francisco Javier López Longo, Joan M Nolla, Marcelino Revenga, Carmen González-Vela, Javier Loricera, Belén Atienza-Mateo, Rosalía Demetrio-Pablo, José Luis Hernández, Miguel A González-Gay, Ricardo Blanco
PURPOSE: To assess efficacy, safety, and cost-effectiveness of adalimumab (ADA) therapy optimization in a large series of patients with uveitis due to Behçet disease (BD) who achieved remission after the use of this biologic agent. DESIGN: Open-label multicenter study of ADA-treated patients with BD uveitis refractory to conventional immunosuppressants. SUBJECTS: Sixty-five of 74 patients with uveitis due to BD, who achieved remission after a median ADA duration of 6 (range, 3-12) months...
March 27, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29596070/chronic-myelomonocytic-leukemia-with-fibrosis-is-a-distinct-disease-subset-with-myeloproliferative-features-and-frequent-jak2-p-v617f-mutations
#13
Gur Deniz, Sanam Loghavi, Guillermo Garcia-Manero, Mark Routbort, Rashmi Kanagal-Shamanna, Andres Quesada, Haitham Khogeer, Sherry Pierce, L Jeffrey Medeiros, Hagop Kantarjian, Joseph D Khoury
A subset of patients with chronic myelomonocytic leukemia (CMML) presents with significance myelofibrosis. In myelodysplastic syndromes, significant myelofibrosis has been associated with adverse outcomes and p53 dysregulation. However, in CMML the clinical and molecular correlates of significant myelofibrosis at presentation remain poorly understood. From a cohort of 651 CMML patients, we identified retrospectively 20 (3.1%) cases with moderate to severe reticulin fibrosis (CMML-F) detected at diagnosis, and we compared them to CMML patients without fibrosis (n=631) seen during the same period...
March 28, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29567676/cancer-associated-rs6983267-snp-and-its-accompanying-long-noncoding-rna-ccat2-induce-myeloid-malignancies-via-unique-snp-specific-rna-mutations
#14
Maitri Y Shah, Manuela Ferracin, Valentina Pileczki, Baoqing Chen, Roxana Redis, Linda Fabris, Xinna Zhang, Cristina Ivan, Masayoshi Shimizu, Cristian Rodriguez-Aguayo, Mihnea Dragomir, Katrien Van Roosbroeck, Maria Ines Almeida, Maria Ciccone, Daniela Nedelcu, Maria Angelica Cortez, Taghi Manshouri, Steliana Calin, Muharrem Muftuoglu, Pinaki P Banerjee, Mustafa H Badiwi, Jan Parker-Thornburg, Asha Multani, James William Welsh, Marcos Roberto Estecio, Hui Ling, Ciprian Tomuleasa, Delia Dima, Hui Yang, Hector Alvarez, M James You, Milan Radovich, Elizabeth Shpall, Muller Fabbri, Katy Rezvani, Leonard Girnita, Ioana Berindan-Neagoe, Anirban Maitra, Srdan Verstovsek, Riccardo Fodde, Carlos Bueso-Ramos, Mihai Gagea, Guillermo Garcia Manero, George A Calin
The cancer-risk-associated rs6983267 single nucleotide polymorphism (SNP) and the accompanying long noncoding RNA CCAT2 in the highly amplified 8q24.21 region have been implicated in cancer predisposition, although causality has not been established. Here, using allele-specific CCAT2 transgenic mice, we demonstrate that CCAT2 overexpression leads to spontaneous myeloid malignancies. We further identified that CCAT2 is overexpressed in bone marrow and peripheral blood of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) patients...
March 22, 2018: Genome Research
https://www.readbyqxmd.com/read/29557496/association-of-bone-marrow-fibrosis-with-inferior-survival-outcomes-in-chronic-myelomonocytic-leukemia
#15
Maliha Khan, Tariq Muzzafar, Hagop Kantarjian, Ifra Badar, Nicholas Short, Xuemei Wang, Kamal Chamoun, Preetesh Jain, Courtney DiNardo, Naveen Pemmaraju, Prithviraj Bose, Gautam Borthakur, Jorge Cortes, Srdan Verstovsek, Guillermo Garcia-Manero, Zeev Estrov
The impact of bone marrow fibrosis grade on the prognosis of patients with chronic myelomonocytic leukemia (CMML) remains controversial. Therefore, we examined the records of 82 patients diagnosed with CMML at our institution and summarized baseline characteristics and molecular profiles by subgroups of absent or mild (grades 0/1) and moderate (grade 2) fibrosis. Cox proportional hazards models were constructed to assess the prognostic significance of fibrosis grade. Grade 2 fibrosis was identified in 63 patients (76...
March 20, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29550383/liposomal-grb2-antisense-oligodeoxynucleotide-bp1001-in-patients-with-refractory-or-relapsed-haematological-malignancies-a-single-centre-open-label-dose-escalation-phase-1-1b-trial
#16
Maro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Michael Andreeff, Marina Konopleva, Miranda Lim, Sherry Pierce, Susan O'Brien, Yesid Alvarado, Srdan Verstovsek, William Wierda, Hagop Kantarjian, Jorge Cortes
BACKGROUND: Activating mutations of tyrosine kinases are common in leukaemias. Oncogenic tyrosine kinases use the growth factor receptor-bound protein 2 (Grb2) for signal transduction, leading to activation of mitogen-activated protein kinase (MAPK) 1 and MAPK3 (ERK2 and ERK1). We hypothesised that inhibition of Grb2 would suppress ERK1 and ERK2 activation and inhibit leukaemia progression. To inhibit Grb2, a liposome-incorporated antisense oligodeoxynucleotide that blocks Grb2 protein expression, BP1001, was developed...
April 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29515765/impact-of-the-number-of-mutations-in-survival-and-response-outcomes-to-hypomethylating-agents-in-patients-with-myelodysplastic-syndromes-or-myelodysplastic-myeloproliferative-neoplasms
#17
Guillermo Montalban-Bravo, Koichi Takahashi, Keyur Patel, Feng Wang, Song Xingzhi, Graciela M Nogueras, Xuelin Huang, Ana Alfonso Pierola, Elias Jabbour, Simona Colla, Irene Gañan-Gomez, Gautham Borthakur, Naval Daver, Zeev Estrov, Tapan Kadia, Naveen Pemmaraju, Farhad Ravandi, Carlos Bueso-Ramos, Ali Chamseddine, Marina Konopleva, Jianhua Zhang, Hagop Kantarjian, Andrew Futreal, Guillermo Garcia-Manero
The prognostic and predictive value of sequencing analysis in myelodysplastic syndromes (MDS) has not been fully integrated into clinical practice. We performed whole exome sequencing (WES) of bone marrow samples from 83 patients with MDS and 31 with MDS/MPN identifying 218 driver mutations in 31 genes in 98 (86%) patients. A total of 65 (57%) patients received therapy with hypomethylating agents. By univariate analysis, mutations in BCOR, STAG2, TP53 and SF3B1 significantly influenced survival. Increased number of mutations (≥ 3), but not clonal heterogeneity, predicted for shorter survival and LFS...
February 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29506939/temporal-trends-between-association-of-evidence-based-treatment-and-outcomes-in-patients-with-non-st-elevation-myocardial-infarction
#18
Belén Alvarez-Alvarez, Charigan Abou Jokh Casas, Jose María Garcia Acuña, Belén Cid Alvarez, Rosa María Agra Bermejo, Alberto Cordero Fort, Moisés Rodríguez Mañero, Francisco Gude Sampedro, José R González-Juanatey
No abstract text is available yet for this article.
June 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29487386/hypomethylating-agents-in-combination-with-immune-checkpoint-inhibitors-in-acute-myeloid-leukemia-and-myelodysplastic-syndromes
#19
REVIEW
Naval Daver, Prajwal Boddu, Guillermo Garcia-Manero, Shalini Singh Yadav, Padmanee Sharma, James Allison, Hagop Kantarjian
Immune checkpoint inhibitors, as single-agent therapy, have shown modest clinical efficacy in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As has been successfully shown in other less immunogenic hematologic malignancies, rationally designed combination approaches may be more effective than single-agent checkpoint inhibitors, and may be the approach to pursue in AML/MDS. Hypomethylating agents (HMAs) such as azacitidine, while enhancing anti-tumor immune response, concurrently dampen immune response by upregulating inhibitory immune checkpoint molecule expression...
May 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29464484/characteristics-and-outcome-of-chronic-myeloid-leukemia-patients-with-e255k-v-bcr-abl-kinase-domain-mutations
#20
Kiran Naqvi, Jorge E Cortes, Raja Luthra, Susan O'Brien, William Wierda, Gautam Borthakur, Tapan Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Mary Beth Rios, Sara Dellasala, Sherry Pierce, Elias Jabbour, Keyur Patel, Hagop Kantarjian
Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in vitro to all TKI. We aimed to study the incidence, prognosis, and response to treatment in patients with E255K/V. We evaluated 976 patients by sequencing of BCR-ABL1 fusion transcript for ABL1 KD mutations. We identified KD mutations in 381 (39%) patients, including E255K/V in 48 (13% of all mutations). At mutation detection, 14 patients (29%) were in chronic phase (CP), 12 (25%) in accelerated phase (AP), and 22 (46%) in blast phase (BP)...
February 20, 2018: International Journal of Hematology
keyword
keyword
35456
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"